Search
etrasimod (Velsipity)
Indications:
- investigational treatment of atopic dermatitis
- ulcerative colitis (FDA-approved)
Contraindications:
- myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or heart failure class III or IV
- history of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker.
Dosage:
- 2 mg PO QD
Adverse effects:
- may increase risk of infections
- unintended additive immune system effects from prior treatment with immunosuppressives or immunomodulators
- immune system effects after stopping etrasimod
- bradyarrhythmia & atrioventricular conduction delays
- hepatotoxicity: increase in serum transaminases
- may increase risk of macular edema
- hypertension
- skin cancer
- posterior reversible encephalopathy syndrome
- may cause a decline in pulmonary function [3]
Mechanism of action:
- sphingosine 1-phosphate receptor 1 (S1PR1) modulator
- activates S1PR subtypes S1PR1, S1PR4 & S1PR5
- with no detectable activity on S1PR2 or S1PR3
- prevents immune cells or lymphocytes from getting into skin
General
dermatologic agent
receptor antagonist
Database Correlations
PUBCHEM cid=44623998
References
- Laub G
Etrasimod Shows Promise for Atopic Dermatitis
New safety and efficacy data highlight potential, Emma Guttman-Yassky explains.
MedPage Today May 24, 2021
https://www.medpagetoday.com/meetingcoverage/aadvideopearls/92764
- Brooks M
FDA Approves New Drug for Ulcerative Colitis.
Medscape. Oct 13, 2023
https://www.medscape.com/viewarticle/997350
- Sandborn WJ et al
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE):
two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet. 2023;401(10383):P1159 April 8.
PMID: 36871574 Free article
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00061-2/fulltext
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Velsipity. tablets, for oral use
https://labeling.pfizer.com/ShowLabeling.aspx?id=19776